Satyashiva Das’ Post

A damaged gut barrier is linked to worse outcomes in #IBD patients. Cutting-edge endoscopic methods, such as probe-based confocal laser endomicroscopy (pCLE), have shown promise in evaluating real-time structural and functional barrier impairment at a cellular level, enabling the prediction of therapy responses and potential negative clinical results. Tools like #Cellvizio can assist with forecasting treatment responses and creating tailored care strategies. Click here to read more: https://hubs.ly/Q02KJ3c70 #functionalimaging Crohn's & Colitis Foundation

On September 16, 1977, Dr. Andreas Gruentzig performed the first percutaneous transluminal coronary angioplasty (PTCA). Since then, #angioplasty has evolved with advancements and today, it’s a cornerstone of #interventionalcardiology. Currently, approximately 1.5 to 2 million angioplasties are performed annually worldwide. #HappyInternationalDayforInterventionalCardiology to all interventional cardiologists! Your dedication to saving lives and improving patient outcomes inspires us to continue innovating. #Biocalculus

🚀 Exciting Development from Ventripoint Diagnostics Ltd. 🚀 We are thrilled to share that our advanced AI-powered heart-scanning software, VMS+4.0, has been submitted to the U.S. Food and Drug Administration (FDA) for clearance as of May 1, 2024. This innovation is poised to revolutionize cardiac diagnostics with precision and ease. 🌟 Spotlight Features of VMS+4.0: VMS Strain and Heat Maps: Our latest software introduces enhanced visualization tools, including strain and heat maps that accurately depict the detailed mechanics of heart muscle movements. These tools offer cardiologists deeper insights into cardiac function, enabling better patient management. Automated Plotting of Key Anatomical Landmarks: With VMS+4.0, the manual plotting of cardiac landmarks is a thing of the past. Our technology automatically identifies and maps critical points within the heart, significantly boosting the confidence, reliability, consistency, and reproducibility of volumetric measurements. This automation not only saves time but also enhances the precision of cardiac assessments. 🔍 These features ensure that VMS+4.0 can deliver MRI-quality images and analyses quickly and reliably, making advanced cardiac care accessible in minutes. 🌍 Global Outreach: As we anticipate FDA approval, our commitment extends beyond borders. Regulatory clearances in the EU, UK, and Canada are also underway, aiming to equip healthcare providers worldwide with our cutting-edge technology. 🇵🇹 Meet Us at AEPC 2024 in Porto: Discover firsthand how VMS+4.0 is setting new standards in cardiac imaging. We’re excited to demonstrate its capabilities and discuss its impact on the future of cardiology. #Ventripoint #HeartHealth #MedicalInnovation #AI #FDA #Cardiology #AEPC2024 🔗 Stay tuned for more updates or reach out to us to learn more!

🚀 Exciting News: Introducing CERCARE MEDICAL NEUROSUITE (CMN) Version 15! We are thrilled to announce the release of CMN Version 15, a major advancement in stroke diagnosis and patient management. This latest update from Cercare Medical brings a host of new features designed to enhance diagnostic accuracy and efficiency, setting new standards in perfusion imaging and analysis. 🔍 Key Features Include: 🔸 CE Marked ASPECTS: Now CE marked for accurate MCA territory estimation on NCCT series.  🔸 New CT Denoising: Enhances image quality with dynamic noise reduction.  🔸 Advanced Thresholding: Improved delay and CBV thresholding with reduced noise and artifacts.  🔸 Hypoperfusion and CBV Index: Comprehensive perfusion data analysis.  LVO Montage & AI-Based LVO Detection: Enhanced visualization and AI-powered detection of large vessel occlusions.  🔸 Cone Beam CT Perfusion: Compatibility with CBCT perfusion. Professor Kim Mouridsen, CEO of Cercare Medical, states, "The release of CMN Version 15 is a significant step forward in enhancing our stroke and oncology solutions. We are now much further integrated into clinical practices around the world, continuously receiving invaluable input from healthcare professionals globally." At Cercare Medical, we remain committed to advancing medical imaging and diagnostic precision, ensuring that cutting-edge technology is both accessible and user-friendly for clinical use. Discover more about CMN Version 15 and its transformative capabilities here : https://lnkd.in/dgEsEhJS #ProductRelease #MedicalImaging #Stroke #HealthcareInnovation #Neuroimaging #PerfusionRevolution #CMNVersion15 

#News Today, Biosense Webster announced the launch of CARTO™ 3 System Version 8, the latest version of the company’s leading three-dimension (3D) heart mapping system used in cardiac ablation procedures. The V8 software has new modules like CARTO ELEVATE™ and CARTOSOUND™ FAM. CARTOSOUND™ FAM introduces #AI to reconstruct left atrial anatomy and simplify workflow. Both modules enhance efficiency, reproducibility, and accuracy for electrophysiologists conducting catheter ablation procedures for #AFib patients. Despite significant progress in the field, #AFib impacts nearly 50 million people worldwide. This underscores the need for new and improved tools that help #EPeeps deliver optimal treatment for cardiac arrhythmias. I’m pleased to see Johnson & Johnson MedTech continue to raise the bar for innovative technology and make a difference for electrophysiologists and patients worldwide. Learn more: https://lnkd.in/gQAyY7Tg #JNJMedTechProud #MyCompany

Exploring Cardiogenic Shock Treatment with Multi-Device Simulation #ComputationalLife In our latest breakthrough, we've digitally replicated a patient in the throes of cardiogenic shock to assess the efficacy of four distinct medical devices. Our visual graphs do more than just depict left ventricular volumes during a cardiac cycle – they provide critical insights that guide physicians towards the most impactful treatment options. The evidence is clear and corroborated by literature: pVADs effectively reduce End-Diastolic Volume (EDV) without significantly affecting End-Systolic Volume (ESV). IABP optimally decreases both EDV and ESV, improving cardiac function. LVADs, with their unique triangular volume profiles, substantially reduce the overall volume in the left ventricle. ECMO, specifically from the right atrium to the femoral artery, increases both ESV and EDV. These simulations are more than data – they are the future of personalized patient care, offering a window into the real-time impact of life-saving interventions. Delve into the intricacies of our pioneering research and be part of the conversation shaping the future of cardiac care. For continuous updates and insights, make sure to follow our LinkedIn page. #DigitalHealth #CardiogenicShock #MedicalSimulation #HealthcareInnovation #IABP #pVAD #LVAD #ECMO #CardiacCare

🚀 Exciting News: Introducing CERCARE MEDICAL NEUROSUITE (CMN) Version 15! We are thrilled to announce the release of CMN Version 15, a major advancement in stroke diagnosis and patient management. This latest update from Cercare Medical brings a host of new features designed to enhance diagnostic accuracy and efficiency, setting new standards in perfusion imaging and analysis. 🔍 Key Features Include: 🔸 CE Marked ASPECTS: Now CE marked for accurate MCA territory estimation on NCCT series.  🔸 New CT Denoising: Enhances image quality with dynamic noise reduction.  🔸 Advanced Thresholding: Improved delay and CBV thresholding with reduced noise and artifacts.  🔸 Hypoperfusion and CBV Index: Comprehensive perfusion data analysis.  LVO Montage & AI-Based LVO Detection: Enhanced visualization and AI-powered detection of large vessel occlusions.  🔸 Cone Beam CT Perfusion: Compatibility with CBCT perfusion. Professor Kim Mouridsen, CEO of Cercare Medical, states, "The release of CMN Version 15 is a significant step forward in enhancing our stroke and oncology solutions. We are now much further integrated into clinical practices around the world, continuously receiving invaluable input from healthcare professionals globally." At Cercare Medical, we remain committed to advancing medical imaging and diagnostic precision, ensuring that cutting-edge technology is both accessible and user-friendly for clinical use. Discover more about CMN Version 15 and its transformative capabilities here : https://lnkd.in/dgEsEhJS #ProductRelease #MedicalImaging #Stroke #HealthcareInnovation #Neuroimaging #PerfusionRevolution #CMNVersion15y

Every wondered what a pulmonary embolus looks like on dynamic PET/CT? It is almost a year since I first rang a referring clinician to tell them that their patient had a PE and was greeted with the question as to whether we had done a VQ scan. Since then I have explained on a number of patients, the visualisation of multiple segmentation perfusion abnormalities on the first pass of the radioactive bolus through the lungs in the absence of clear reasons for this on correlative CT. At the Melbourne Theranostic Innovation Centre we are learning the advantages of "all organ" dynamic imaging as we go. In this case the region of interest wasn't the chest and would never have been included in dynamic imaging on a conventional field-of-view scanner. At least in Australia, there is no reimbursement for doing other than a delayed "whole body" scan which typically includes only vertex to upper thighs. We feel that there are major benefits to patient care in doing dynamic imaging in many clinical situations, including evaluation perfusion of lesions, their relation to vascular structures, particularly in patients with contraindications to contrast and for pharmacological interventions like diuretic renograms. More to come, I am sure.

The BUBL Study (https://bit.ly/4cA0FkW #NCT04604015) enrolled 154 subjects across six sites to compare standard TTE imaging with our NG2 Intelligent Ultrasound. The results are groundbreaking: 🔹 NG2 demonstrated over 3X the detection rate for RLS compared to TTE. 🔹 It detected more than twice the number of patients at the highest risk of stroke recurrence. 🔹 Achieved 2.7X detection of intervenable shunts. These findings highlight the transformative potential of NG2 Intelligent Ultrasound in stroke diagnosis and patient care. #BUBL #stroke #PFO #neurasignal

Study seeks to develop and validate a #DeepLearning model to predict hemorrhagic transformation after endovascular thrombectomy (EVT), which may help in medical management after EVT. (JoonNyung Heo et al.) #EuropeanRadiology 🔗 https://buff.ly/41xABCm